

DAFTAR PUSTAKA

1. Jayaraj J, Davatyan K, Subramanian, Priya J. Epidemiology of Myocardial Infarction. In : Myocardial Infarction. 2018 [Online]. Tersedia di <https://www.researchgate.net/publication/330089690> Epidemiology of Myocardial Infarction [Diakses pada September 2019]
2. Mendis S, Thygesen K, Kuulasmaa K, Giampaoli S, Mahonen M, Blackett KN, et al. World Health Organization definition of myocardial infarction: 2008-09 revision. *Int J Epidemiol*. 2011;40(1):139–46.
3. Kristian Thygesen, Joseph S Alpert, Allan S Jaffe, Bernard R Chaitman, Jeroen J Bax, David A Morrow HDW. Fourth universal definition of myocardial infarction. *Eur Heart J*. 2019;40(3):237–269.
4. Benjamin EJ, Muntner P, Alonso A, Bittencourt MS, Callaway CW, Carson AP, et al. Heart Disease and Stroke Statistics-2019 Update: A Report From the American Heart Association. *Circulation*. 2019;139(10):56-66.
5. Balitbang Kemenkes RI. Riset Kesehatan Dasar. Jakarta: Kementerian Kesehatan Republik Indonesia; 2018.
6. Balitbang Kemenkes RI. Riset Kesehatan Dasar. Jakarta: Kementerian Kesehatan Republik Indonesia; 2013.
7. Pusat Data Dan Informasi Kemenkes RI. Gambaran Penyakit Tidak Menular Di Rumah Sakit Di Indonesia. 2012.
8. Mechanic OJ, Grossman SA. Acute Myocardial Infarction. (2019). In: *StatPearls*. Treasure Island (FL) : StatPearls Publishing.
9. Ditjen Bina Kefarmasian dan Alat Kesehatan. Pharmaceutical Care untuk Pasien Penyakit Jantung Koroner : Fokus Sindrom Koroner Akut. Jakarta: Departemen Kesehatan; 2006.
10. Skovsted GF, Kruse LS, Berchtold LA, Grell AS, Warfvinge K, Edvinsson L. Myocardial ischemia-reperfusion enhances transcriptional expression of endothelin-1 and vasoconstrictor ETB receptors via the protein kinase MEK-ERK1/2 signaling pathway in rat. *PLoS One*. 2017;12(3):1–18.
11. Rossi GP, Seccia TM, Albertin G, Pessina AC. Measurement of endothelin: Clinical and research use. *Ann Clin Biochem*. 2000;37(5):608–26.
12. D. Giannesi, S. Del Ry, R.L. Vitale. The role of endothelins and their receptors in heart failure. *Pharmacol Res*. 2001;43(2):111–26.
13. Loennechen JP, Stoylen A, Beisvag V, Wisloff U, Ellingsen O. Regional expression of endothelin-1, ANP, IGF-1, and LV wall stress in the infarcted rat heart. *Am J Physiol - Hear Circ Physiol*. 2001;280(6 49-6):2902–10.
14. Khan IA. Role of endothelin-1 in acute myocardial infarction. *Chest*. 2005;127(5):1474–6.
15. Berger R, Pacher R. The role of the endothelin system in myocardial infarction - New therapeutic targets? *Eur Heart J*. 2003;24(4):294–6.
16. Pfeffer MA, editors. ACE inhibitors in acute myocardial infarction: Patient selection and timing. *Circulation*. 1998;97(22):2192–4.
17. Perhimpunan Dokter Spesialis Kardiovaskular Indonesia. Pedoman Tatalaksana Sindrom Koroner Akut. 4th ed. Jakarta: PERKI; 2018.

18. Kementerian Kesehatan Republik Indonesia. Formularium Nasional. Kepmenkes RI Nomor HK.02.02/MENKES/137/2016. Jakarta; 2015.
19. Bayir Y, Cadirci E, Suleyman H, Halici Z, Keles MS. Effects of Lacidipine, Ramipril and Valsartan on Serum BNP Levels in Acute and Chronic Periods Following Isoproterenol-Induced Myocardial Infarction in Rats. *Eurasian J Med.* 2009;44–8.
20. Desideri G, Grassi D, Croce G, Bocale R, Tiberti S, Evangelista S, et al. Different effects of angiotensin converting enzyme inhibitors on endothelin1 and nitric oxide balance in human vascular endothelial cells: Evidence of an oxidant-sensitive pathway. *Mediators Inflamm.* 2008;1–7.
21. Keles MS, Bayir Y, Suleyman H, Halici Z. Investigation of effects of Lacidipine, Ramipril and Valsartan on DNA damage and oxidative stress occurred in acute and chronic periods following isoproterenol-induced myocardial infarct in rats. *Mol Cell Biochem.* 2009;328(1–2):109–17.
22. Frangogiannis NG. Pathophysiology of myocardial infarction. *Compr Physiol.* 2015;5(4):1841–75.
23. Antman E, Bassand JP, Klein W, Ohman M, Lopez Sendon JL, Rydén L, et al. Myocardial infarction redefined - A consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. *J Am Coll Cardiol.* 2000;36(3):959–69.
24. Thygesen K, Alpert JS, Jaffe AS, Chaitman BR, Bax JJ, Morrow DA, et al. Circulation ESC / ACC / AHA / WHF EXPERT CONSENSUS DOCUMENT Fourth Universal Definition of Myocardial Infarction. *Circulation.* 2018; (138): 1–34.
25. McCarthy CP, Januzzi JL, Gaggin HK. Type 2 myocardial infarction: An evolving entity. *Circ J.* 2018;82(2):309–15.
26. Saleh M, Ambrose JA. Understanding myocardial infarction [version 1; referees: 2 approved]. *F1000Research.* 2018;7:1–8.
27. Gara PTO, Kushner FG, Ascheim DD, Casey DE, Mina K, Lemos JA De, et al. AHA Guidelines - STEMI. *Circulation* [Internet]. 2013;127(4):362–425. Tersedia di <https://www.ahajournals.org/doi/10.1161/CIR.0b013e3182742cf6> [Diakses pada September 2019].
28. National Institute for Health and Care Excellence (2013). Myocardial infarction with ST-segment elevation: acute management. NICE Clin Guidel. Tersedia di <https://www.nice.org.uk/guidance/cg167> [Diakses pada September 2019].
29. CAD: Acute Coronary Syndrome. Cleveland Clinic. Tersedia di <https://my.clevelandclinic.org/health/diseases/16713-cad-acute-coronarysyndrome> [Diakses pada September 2019].
30. Foth C, Mountfort S. Acute Myocardial Infarction ST Elevation (STEMI). (2018). In: StatPearls. Treasure Island (FL): StatPearls Publishing.
31. Ambrose JA, Singh M. Pathophysiology of coronary artery disease leading to acute coronary syndromes. *F1000Prime Rep.* 2015;7:1–5.
32. Ahmad YA, Ali MT (2019). Non-ST Elevation Myocardial Infarction: Diagnosis and Management, *Myocardial Infarction.* IntechOpen. Tersedia di https://www.intechopen.com/books/myocardial_infarction/nonst-

- [elevationmyocardial-infarction-diagn.](#) [Diakses pada September 2019].
33. Sjahrudin, Harun, Alwi I. Infark miokard akut tanpa elevasi ST. dalam : Buku Ajar Ilmu Penyakit Dalam. Jakarta: FKUI; 2006.
 34. Amsterdam EA, Wenger NK, Brindis RG, Casey DE, Ganiats TG, Holmes DR, et al (2014). AHA/ACC guideline for the management of patients with non-ST-elevation acute coronary syndromes: Executive summary: a report of the American College of Cardiology/ American Heart Association Task Force on Practice Guidelines. *Circulation*. Tersedia di <https://www.ahajournals.org/doi/full/10.1161/cir.000000000000133> [Diakses pada September 2019].
 35. Loutfi M, Ashour S, El-Sharkawy E, El-Fawal S, El-Touny K. Identification of high-risk patients with non-ST segment elevation myocardial infarction using strain Doppler echocardiography: Correlation with cardiac magnetic resonance imaging. *Clin Med Insights Cardiol*. 2016;10(LV):51–9.
 36. Ojha N, Dharmoon AS (2019). In: *StatPearls*. Treasure Island (FL) : StatPearls Publishing.
 37. Huma S, Tariq R, Amin Dr. F, Mahmood Dr. KT. Modifiable and nonmodifiable predisposing risk factors of myocardial infarction -A review. *J Pharm Sci Res*. 2012;4(1):1649–53.
 38. Iorga A, Cunningham CM, Moazeni S, Ruffenach G, Umar S, Eghbali M. The protective role of estrogen and estrogen receptors in cardiovascular disease and the controversial use of estrogen therapy. *Biol Sex Differ*. 2017;8(1):33.
 39. Anand SS, Islam S, Rosengren A, Franzosi MG, Steyn K, Yusufali AH, Keltai M, Diaz R, Rangarajan S, Yusuf S, editors. INTERHEART Investigators. Risk factors for myocardial infarction in women and men: insights from the INTERHEART study. *Eur. Heart J*. 2008; 29(7):932-40
 40. Libby P. Mechanisms of acute coronary syndromes and their implications for therapy. *N Engl J Med*. 2013;368(21):2004–13.
 41. Reed, Grant W, Rossi, Jeffrey E, Cannon CP. Acute myocardial infarction. *Lancet*. 2017;389:197-210.
 42. Ascheim DD, Fesmire FM, Kushner FG, Zhao DX, Ornato JP, Chung MK, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction. *J Am Coll Cardiol*. 2012;61(4):78–140.
 43. Basit H, Malik A, Huecker MR (2019). Non ST Segment Elevation (NSTEMI) Myocardial Infarction. In: *StatPearls*. Treasure Island (FL): StatPearls Publishing.
 44. W Sudoyo A, Bambang S, Idrus A, et al. *Buku Ajar Ilmu Penyakit Dalam Jilid II*. 5th ed. Jakarta: Interna Publishing; 2010.
 45. W Sudoyo A, Bambang S, Idrus A, et al. *Buku Ajar Ilmu Penyakit Dalam*. 4th ed. Jakarta: Pusat Penerbitan Ilmu Penyakit Dalam Fakultas Kedokteran Universitas Indonesia; 2006.
 46. Barstow C, Rice M, McDivitt JD. Acute coronary syndrome: Diagnostic evaluation. *Am Fam Physician*. 2017;95(3):170–7.

47. Guyton & Hall. Buku Ajar Fisiologi Kedokteran. 12th ed. M. Djauhari Widjajakusumah AT, editor. Singapore: Saunders Elsevier; 2014: 234–6.
48. Neal L. Benowitz. Obat Antihipertensi. Dalam: Bertram G. Katzung, editors. Farmakologi Dasar dan Klinik. 10th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2007 : 177-80.
49. Edwin K Jackson. Renin and Angiotensin. In: Laurence L. Brunton, John S. Lazo KLP, editors. Goodman & Gilman The Pharmacological Basis of Therapeutics. 11th ed. New York: McGraw-Hill Education; 2005:804.
50. FDA. ALTACE® Tablets. Tersedia di http://www.accessdata.fda.gov/drugsatfda_docs/label/2011/022021s0071bl [Diakses pada September 2019].
51. Mohamed Saleem TS, Bharani K, Gauthaman K. ACE inhibitors - Angiotensin II receptor antagonists: A useful combination therapy for ischemic heart disease. *Open Access Emerg Med.* 2010;2:51–9.
52. Herman LL, Bashir K. Angiotensin Converting Enzyme Inhibitors (ACEI) (2019). In: StatPearls. Treasure Island (FL) : StatPearls Publishing.
53. Simcha Meisel AS and TRT. Clinical Pharmacokinetics of Ramipril. *Clio Pharmacokinet.* 1994;26(1):7–15.
54. Filho HGL, Ferreira NL, de Sousa RB, de Carvalho ER, Lobo PLD, Filho JGL. Experimental model of myocardial infarction induced by isoproterenol in rats. *Brazilian J Cardiovasc Surg.* 2011;26(3):469–76.
55. Li H, Xie YH, Yang Q, Wang SW, Zhang B Le, Wang JB, et al. Cardioprotective effect of paeonol and danshensu combination on isoproterenol-induced myocardial injury in rats. *PLoS One.* 2012;7(11):1–10.
56. Rathore N, John S, Kale M, Bhatnagar D. Lipid Peroxidation and Antioxidant Anzymes in Isoproterenol Induced Oxidative Stress in Rat Tissues. *Pharmacol Res.* 1998;38:297-303.
57. S Naranjan, Dhalla, Temsah RM, Netticadan T. Role of oxidative stress in cardiovascular diseases. *Res J Pharm Biol Chem Sci.* 2013;4(3):870–81.
58. Remondino A, Kwon SH, Communal C, Pimentel DR, Sawyer DB, Singh K, et al. β -adrenergic receptor-stimulated apoptosis in cardiac myocytes is mediated by reactive oxygen species/c-Jun NH₂-terminal kinase-dependent activation of the mitochondrial pathway. *Circ Res.* 2003;92(2):136–8.
59. Upaganlawar A, Gandhi H, Balaraman R. Isoproterenol induced myocardial infarction: Protective role of natural products. *J Pharmacol Toxicol.* 2011;6(1):1–17.
60. Devika P.T. and Prince P.S.M. Epigallocatechingallate (EGCC) Prevents Isoproterenol Induced Cardiac Toxicity by Stabilizing Cardiac Marker Enzymes and Membrane Bound ATPases. *J. Pharm Pharmacogn.* 2008;60:125-133.
61. Adeoye B, Ajibade T, Asenuga E, Adejumobi O, Oyagbemi A, Omobowale T, et al. Enalapril Confers Protective Effect on Isoproterenol-Induced Myocardial Infarction in Rats through Downregulation of Cardiac Troponin, C-reactive Protein, Upregulation of IL-10 β as Well as Anti-Oxidant and Anti-inflammatory Activities. *Int J Biochem Res Rev.* 2018;20(3):1– 20.
62. Etkileri SU. Levels in Acute and Chronic Periods Following IsoproterenolInduced. *Eurasian J Med.* 2009;44–8.

63. Houde M, Desbiens L, D'Orleans-Juste P. Endothelin-1: Biosynthesis, Signaling and Vasoreactivity. *Adv Pharmacol.* 2016;77:143–75.
64. Tasaka K. The Control of Endothelin-1 Secretion Key Words : NH2. 1994;25(6).
65. Kolettis, Theofilos M, Barton, Matthias, Langleben, et al. Endothelin in coronary artery disease and myocardial infarction. *Cardiol Rev.* 2013;21(5):249-256.
66. Lewicki L, Siebert J, Marek-Trzonkowska N, Masiewicz E, Kolinski T, Reiwer-Gostomska M, et al. Elevated serum tryptase and endothelin in patients with ST segment elevation myocardial infarction: Preliminary report. *Mediators Inflamm.* 2015:1-7.
67. Alonso D, Radomski MW. The nitric oxide-endothelin-1 connection. *Heart Fail Rev.* 2003;8(1):107–15.
68. Bourque SL, Davidge ST, Adams MA. The interaction between endothelin1 and nitric oxide in the vasculature: New perspectives. *Am J Physiol - Regul Integr Comp Physiol.* 2011;300(6):1288–95.
69. Tracy E, Hunley, Shigeki Iwasaki, Toshio Homma VK. Nitric oxide and endothelin in pathophysiological settings. *Pediatr Nephrol.* 1995;9(2):235–4
70. Kelly LK, Wedgwood S, Steinhorn RH, Black SM. Nitric oxide decreases endothelin-1 secretion through the activation of soluble guanylate cyclase. *Am J Physiol - Lung Cell Mol Physiol.* 2004;286(5 30-5):984–91
71. Momose N, Fukuo K, Morimoto S, Ogihara T. Captopril inhibits endothelin-1 secretion from endothelial cells through bradykinin. *Hypertension.* 1993;21(6):921–4.
72. Oh PC, Sakuma I, Hayashi T, Koh KK. Angiotensin converting enzyme inhibitors remain the first treatment of choice. *Korean J Intern Med.* 2016;31(2):237–41.
73. Kobayashi N, Hara K, Higashi T, Matsuoka H. Effects of imidapril on endothelin-1 and ACE gene expression in failing hearts of salt-sensitive hypertensive rats. *Am J Hypertens.* 2000;13(10):1088–96.
74. Dorland. *Kamus Saku Kedokteran Dorland.* Edisi 28. Mahode AA, editor. Jakarta: EGC; 2011.
75. Widyaningsih W, Sugiyanto, Widyarini S, Pramono S, editors. *Isoproterenol sebagai model infark miokardial akut pada tikus wistar.* Prosiding Seminar Nasional Peluang Herbal Sebagai Alternatif Medicine; September 2015; Fakultas Farmasi Universitas Wahid Hasyim. Indonesia: Neliti; 2015.
76. Flora L, Marasciulo, Monica Montagnani MAP. Endothelin-1: The Yin and Yang on Vascular Function. *Current Medicinal Chemistry.* 2006;13(14):1655–65.
77. Laurence D, Bacharach A. *Text book of evaluation of drug activities.* New York: Academic Press; 1964.
78. Giroux MC, Hélie P, Burns P, Vachon P. Anesthetic and pathological changes following high doses of ketamine and xylazine in Sprague Dawley rats. *Exp Anim.* 2015;64(3):253–60.
79. Saputri K. *Teknik Eutanasi dan Nekropsi Tikus (Rattus Novergicus) di National Laboratory Animal Center (NLAC) Mahidol University, Thailand Periode 20 November - Desember 2017.* Gadjah Mada; 2018.

80. Lim KA, Kim KC, Cho MS, Lee BE, Kim HS, Hong YM. Gene expression of endothelin-1 and endothelin receptor A on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. *Korean Circ J*. 2010;40(9):459–64.
81. Manea SA, Todirita A, Manea A. High glucose-induced increased expression of endothelin-1 in human endothelial cells is mediated by activated CCAAT/enhancer-binding proteins. *PLoS One*. 2013;8(12).
82. Mahboudi H, Heidari NM, Rashidabadi ZI, Anbarestani AH, Karimi S, Darestani KD. Prospect and Competence of Quantitative Methods via Real-time PCR in a Comparative Manner: An Experimental Review of Current Methods. *Open Bioinforma J*. 2018;11(1):1–11.
83. Setianto BY, Hartopo AB, Sukmasari I, Puspitawati I. On-admission high endothelin-1 level independently predicts in-hospital adverse cardiac events following ST-elevation acute myocardial infarction. *Int J Cardiol* [Internet]. 2016;220:72–6
84. Eitel I, Nowak M, Stehl C, Adams V, Fuernau G, Hildebrand L, et al. Endothelin-1 release in acute myocardial infarction as a predictor of long-term prognosis and no-reflow assessed by contrast-enhanced magnetic resonance imaging. *Am Heart J*. 2010;159(5):882–90.
85. Enseleit F, Lüscher TF, Ruschitzka F. Angiotensin-converting enzyme inhibition and endothelial dysfunction: Focus on ramipril. *Eur Hear Journal, Suppl*. 2003;5(A):31–6.
86. Ancion A, Tridetti J, Nguyen Trung M-L, Oury C, Lancellotti P. A Review of the Role of Bradykinin and Nitric Oxide in the Cardioprotective Action of Angiotensin-Converting Enzyme Inhibitors: Focus on Perindopril. *Cardiol Ther*. 2019;8(2):179–91.
87. Lobo R, Chandrasekhar Sagar B, Shenoy C. Bio-tea prevents membrane destabilization during Isoproterenol-induced myocardial injury. *J Microsc Ultrastruct* [Internet]. 2017;5(3):146. Tersedia di <http://dx.doi.org/10.1016/j.jmau.2016.09.001> [Diakses pada September 2019].
88. Comini L, Bachetti T, Cargnoni A, Bastianon D, Gitti GL, Ceconi C, et al. Therapeutic modulation of the nitric oxide: all ace inhibitors are not equivalent. *Pharmacol Res*. 2007;56(1):42–8.
89. Fiuza M, editor. *Cardiotoxicity of Oncologic Treatments*. Croatia: InTech; 2012:29.
90. Rosiansky-Sultan M, Klipper E, Spanel-Borowski K, Meidan R. Inverse relationship between nitric oxide synthases and endothelin-1 synthesis in bovine corpus luteum: Interactions at the level of luteal endothelial cell. *Endocrinology*. 2006;147(11):5228–35.
91. Sud N, Black SM. Endothelin-1 impairs nitric oxide signaling in endothelial cells through a protein kinase cδ-dependent activation of STAT3 and decreased endothelial nitric oxide synthase expression. *DNA Cell Biol*. 2009;28(11):543–53.
92. Henry RB, Mark VZ. Reseptor Obat dan Farmakodinamik. Dalam: Bertram G. Katzung, editors. *Farmakologi Dasar dan Klinik*. 10th ed. Jakarta: Penerbit Buku Kedokteran EGC; 2007: 10-3.